Everbright maintains Buy for WuXi Biologics stock, citing RMB 11.79 billion revenue

Published on 10/13/2026 at 01:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted net profit rose 38.40 percent in the first half of 2026. WuXi Biologics stock had HKD 218.2 billion market value on October 12, 2026.

Key points in brief

Everbright Securities maintained a Buy rating after WuXi Biologics reported first-half 2026 revenue of RMB 11.79 billion.
Adjusted net profit reached RMB 3.31 billion, up 38.40 percent year over year in the first half of 2026.
The last Lang & Schwarz price was EUR 6.04 on October 12, 2026, while Hong Kong market capitalization stood at HKD 218.2 billion.

WuXi Biologics, KYG970081173, Illustration mit AI erstellt.

Everbright Securities maintained a Buy rating on WuXi Biologics stock and cited RMB 11.79 billion in first-half 2026 revenue in a report dated October 11, 2026, according to Futubull. The report also raised adjusted net profit forecasts for 2026 and 2027 to RMB 5.82 billion and RMB 7.10 billion.

Three milestones shape the story

On August 25, 2026, WuXi Biologics reported first-half revenue of RMB 11.79 billion, up 18.40 percent year over year, according to Moomoo. On September 24, 2026, the company said its Wuxi Mashan facilities passed a two-week US FDA GMP inspection, covering multiple FDA-approved biologics, according to WuXi Biologics. On October 11, 2026, Everbright Securities maintained its Buy rating while highlighting adjusted net profit of RMB 3.31 billion in the first half.

What does the backlog mean for growth?

The order book provides the clearest operating counterweight to the slower reported profit increase. Outstanding orders reached USD 25.10 billion at the end of the first half of 2026, including USD 5.50 billion scheduled for delivery within three years, according to Futubull. The same report said the company expects to execute 34 PPQ projects during 2026 and had 78 Phase III clinical programs.

Margins improved, but profit was mixed

Gross profit rose 28.10 percent year over year to RMB 5.40 billion in the first half of 2026, while gross margin expanded 3.50 percentage points to 46.20 percent, according to Moomoo. Net profit attributable to owners rose 4.30 percent to RMB 2.40 billion, with foreign-exchange losses and fair-value losses on equity investments weighing on the result.

Euro quote from October 12

The last Lang & Schwarz price was EUR 6.04 on October 12, 2026 at 10:57 p.m. CEST. Hong Kong trading data showed a market capitalization of HKD 218.2 billion and a 52-week range of HKD 28.48 to HKD 58.00 on October 12, 2026. The further course of trading is shown by the continuously updated real-time quote of WuXi Biologics stock.